ABT-267

Base Information

Chemical Name:ABT-267
CAS No.:1258226-87-7
Molecular Formula:C50H67N7O8
Molecular Weight:894.11
Hs Code.:
Mol file:1258226-87-7.mol

Synonyms:ABT-267;ombitasvir;Ombitasvir(ABT-267);2,2'-[[(2S,5S)-1-[4-(1,1-Dimethylethyl)phenyl]-2,5-pyrrolidinediyl]di-4,1-phenylene]bis[N-(methoxycarbonyl)-L-valyl-L-prolinamide

Suppliers and Price of ABT-267

Supply Marketing:

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

TRC
Ombitasvir
25mg
$ 1390.00

DC Chemicals
Ombitasvir >98%
250 mg
$ 1200.00

Crysdot
Ombitasvir(ABT-267) 98+%
100mg
$ 729.00

Crysdot
Ombitasvir(ABT-267) 98+%
50mg
$ 424.00

Crysdot
Ombitasvir(ABT-267) 98+%
25mg
$ 236.00

ChemScene
Ombitasvir 99.79%
50mg
$ 530.00

ChemScene
Ombitasvir 99.79%
10mg
$ 150.00

ChemScene
Ombitasvir 99.79%
5mg
$ 90.00

ChemScene
Ombitasvir 99.79%
100mg
$ 940.00

Cayman Chemical
Ombitasvir ≥98%
5mg
$ 553.00

Total 51 raw suppliers

Chemical Property of ABT-267

Chemical Property:

Boiling Point:1065.6±65.0 °C(Predicted)
PKA:10.92±0.46(Predicted)
PSA：178.72000
Density:1.223±0.06 g/cm3(Predicted)
LogP:8.55570
Storage Temp.:-20°C Freezer, Under inert atmosphere
Solubility.:DMSO (Slightly), Methanol (Slightly)

Purity/Quality:

99%, ^*data from raw suppliers

Ombitasvir ^*data from reagent suppliers

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:: SDS file from LookChem

Useful:

Description Ombitasvir hydrate is a NS5A non-nucleoside polymerase inhibitor which is approved as part of a four drug combination for the treatment of adults with genotype 1 hepatitis C virus infection including those with compensated cirrhosis. The four drug combination treatment consists of ombitasvir, paritaprevir (XXVII), ritonavir, and dasabuvir (X). This combination treatment is marketed as Viekira Pak and was developed by Abbvie as an all oral treatment that eliminates the need for pegylated interferon- a injections.
Uses Ombitasvir is a pharmaceutical drug that is used in the treatment of hepatitis C virus in patients with HCV genotype 1 infection. It inhibits an important viral phosphoprotein, NS5A, which is involved in viral replication, assembly, and secretion.
Drug interactions Potentially hazardous interactions with other drugs See also ritonavir interactions. Ombitasvir: Antibacterials: concentration possibly reduced by rifampicin - avoid. Antidepressants: concentration possibly reduced by St John’s wort - avoid. Antiepileptics: concentration reduced by carbamazepine - avoid, concentration possibly reduced by fosphenytoin, phenobarbital, phenytoin and primidone - avoid. Diuretics: concentration of furosemide reduced (reduce furosemide dose). Immunosuppressants: increases concentration of ciclosporin (reduce ciclosporin dose by a fifth); everolimus (avoid); sirolimus and tacrolimus (reduce dose and use only if benefit outweighs risk - see SPC). Oestrogens: avoid with ethinyloestradiol. Statins: avoid with atorvastatin and simvastatin. Paritaprevir: Antibacterials: avoid with clarithromycin; concentration possibly reduced by rifampicin - avoid. Antidepressants: concentration possibly reduced by St John’s wort - avoid. Antiepileptics: concentration reduced by carbamazepine - avoid; possibly reduced by fosphenytoin, phenobarbital, phenytoin and primidone - avoid. Antifungals: concentration of both drugs increased with ketoconazole and possibly itraconazole and posaconazole - avoid. Antivirals: concentration increased by atazanavir; concentration increased by darunavir and concentration of darunavir decreased; avoid with efavirenz, etravirine, indinavir, nevirapine, saquinavir and tipranavir; concentration increased by lopinavir - avoid. Diuretics: concentration of furosemide increased (reduce furosemide dose). Immunosuppressants: increases concentration of ciclosporin (reduce ciclosporin dose by a fifth); everolimus (avoid); sirolimus and tacrolimus (reduce Antidepressants: concentration possibly reduced by St John’s wort - avoid. Antiepileptics: concentration reduced by carbamazepine - avoid; possibly reduced by fosphenytoin, phenobarbital, phenytoin and primidone - avoid. Antifungals: concentration of both drugs increased with ketoconazole and possibly itraconazole and posaconazole - avoid. Antivirals: concentration increased by atazanavir; concentration increased by darunavir and concentration of darunavir decreased; avoid with efavirenz, etravirine, indinavir, nevirapine, saquinavir and tipranavir; concentration increased by lopinavir - avoid. Diuretics: concentration of furosemide increased (reduce furosemide dose). Immunosuppressants: increases concentration of ciclosporin (reduce ciclosporin dose by a fifth); everolimus (avoid); sirolimus and tacrolimus (reduce

Technology Process of ABT-267

There total 13 articles about ABT-267 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

: 1258235-06-1
4,4’-((2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl)dianiline

: 181827-47-4
(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidine-2-carboxylic acid

: 1258226-87-7
dimethyl (2S,2′S)-1,1′-((2S,2′S)-2,2′-(4,4′-((2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azane-diyl)bis(oxomethylene)bis(pyrrolidine-2,1-diyl)bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate

Guidance literature:: With triethylamine; HATU; In N,N-dimethyl-formamide; at 20 ℃; for 1.5h; Reagent/catalyst; Solvent; Temperature;

Reference yield:

: (2S,2′S)-tert-butyl 2,2′-(4,4′-(trans-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene)bis(azanediyl)bis(oxomethylene))dipyrrolidine-1-carboxylate

: 111398-44-8,74761-42-5
N-methoxycarbonyl-L-valine

: 1258226-87-7
dimethyl (2S,2′S)-1,1′-((2S,2′S)-2,2′-(4,4′-((2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azane-diyl)bis(oxomethylene)bis(pyrrolidine-2,1-diyl)bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate

Guidance literature:: (2S,2′S)-tert-butyl 2,2′-(4,4′-(trans-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene)bis(azanediyl)bis(oxomethylene))dipyrrolidine-1-carboxylate; With trifluoroacetic acid; In dichloromethane; at 20 ℃; for 1h; Inert atmosphere;

N-methoxycarbonyl-L-valine; With 4-methyl-morpholine; 1-hydroxybenzotriazol-hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; N,N-dimethyl-formamide; at 0 - 20 ℃; for 16h; Inert atmosphere;
DOI:10.1021/jm401398x

Reference yield:

: 72-18-4,25609-85-2,7004-03-7,921-10-8
L-valine

: 1258226-87-7
dimethyl (2S,2′S)-1,1′-((2S,2′S)-2,2′-(4,4′-((2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl)bis(4,1-phenylene))bis(azane-diyl)bis(oxomethylene)bis(pyrrolidine-2,1-diyl)bis(3-methyl-1-oxobutane-2,1-diyl))dicarbamate

Guidance literature:: Multi-step reaction with 4 steps

1.1: sodium hydroxide; sodium carbonate / 0.25 h

1.2: 0.5 h / 15 - 20 °C

2.1: 1-hydroxy-1H-benzotriazole hydrate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride / N,N-dimethyl-formamide / 0.58 h

2.2: 2 h / 13 - 20 °C

3.1: hydrogen; 5% palladium on aluminium / tetrahydrofuran / 15 h / 20 °C / 2311.54 Torr

4.1: HATU; triethylamine / N,N-dimethyl-formamide / 1.5 h / 20 °C

With 5% palladium on aluminium; 1-hydroxy-1H-benzotriazole hydrate; hydrogen; sodium carbonate; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; HATU; sodium hydroxide; In tetrahydrofuran; N,N-dimethyl-formamide;